CLOAR *
Manufacturer Details
GENZYME CORPORATION INC.
Genzyme Corpn.Inc.
Compositions:
Clofarabine 1mg/ml solution for injection in 20 ml vials,
Strength
|
Rate
|
Packing Style
|
1mg/ml
|
0.00
|
in 20 ml vials
|
List of Related Indications:
- Acute lymphoblastic leukaemia ( ALL )
List Of Drugs:
- Clofarabine - Purine Analogs and Related Agents - Antimetabolites
Indication Type Description:
Indication:
Acute lymphoblastic leukemia ALL
Adverse Reaction:
Most common adverse effects are-
GI tract symptoms , including vomiting, nausea, and diarrhea
Haematologic effects, including anemia, leukopenia, thrombocytopenia, neutropenia, annd fabrile neutropenia
Cardiovascular -
Flushing 15% hypertension 10% tachycardia 30%
CNS -
Anxiety 20% depression 10% dizziness 13% headache 40% irritabilty 10%
Dermatologic -
Confusion 10% dermatitis 35% dry skin 8% erythema 15% petechiae 25% pruritus 40%
GI
Abdominal pain 30% constipation 18% diarrhea 45% nausea 65% vomiting 75%
GU
Hematuria 14% febrile neutropenia 50%
Hepatic -
Hepatomegaly 12% jaundice 12%
Metabolic /nutrition
Anorexia 25% edema 15%
Musculoskeletal
Arthalgia 10% back pain 10% myalgia 10% pain in limb 25%
Respiratory
Cough 15% epistaxis 25% respiratory distress 11%
Miscellaneous
Fatigue 30% injection site pain 12% pyrexia 35% rigors 35%
Contra-Indications:
Special Precautions/Warnings-
Administeration- administer clofarabine under the supervision of qualifed physician
Bone marrow depression- anticipate suppression of bone marrow function. appears to be
reversible and dose dependent
Tumor lysis syndrome and other adverse reactions- administration of clofarabine results in rapid reduction of peripheal leukemia cells. Evaluate patients undergoing treatment with clofarabine and monitor for signs and symptoms of tumor lysis syndrome.
Renal hepatic function impairment - use caution when administering to this population
Pregnancy - clofarabine may cause fetal harm when administered to pregnant woman. Excercise caution
Lactation- Women treated with clofarabine should not breast feed
Children- safety and efficacy has not been established
Monitoring- obtain complete blood counts and platelet counts t regular intervals during
clofarabine therapy
Dosages/ Overdosage Etc:
Indication
Acute lymphoblastic leukemia (ALL )
Dosage-
Recommended dose 52mg/m2 administered by intravenous infusion over a period over 2 hours daily for 5 consecutive days. Treatment cycles are repeated following recovery or return to baseline organ function, aprox every 2 to 6 weeks.
Patient Information:
1. Patients receving clofarabine may expereience vomiting and and diarrhea. Advice the patients to report to their doctor to avoid dehydration.
2. Patients may experience symptoms of lightheadeness ,fainting,spells or decreased urine out put. Patients may develop hypotension during the period of treatment, consult your doctor.
3. Closely monitor patients taking medicines known to affect blood pressure or cardiac function during administration of clofarabine .
4. Advice patients to use effective contraceptive measures to prevent pregnancy.
Pregnancy and lactation:
Pregnancy -
Clofarabine may cause fetal harm when administered to pregnant woman. Excercise
caution
Lactation-
Women treated with clofarabine should not breast feed
Children-
Safety and efficacy has not been established